{"id":"temsirolimus-cci-779","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"5-20%","effect":"Vomiting"},{"rate":"5-20%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Anorexia"},{"rate":"5-20%","effect":"Hypertension"},{"rate":"5-20%","effect":"Dyspnea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the mTOR pathway, temsirolimus reduces the growth and proliferation of cancer cells. This is achieved by blocking the activity of the mTOR protein, which is a key regulator of cell growth and metabolism. As a result, temsirolimus can help to slow down or stop the growth of cancer cells.","oneSentence":"Temsirolimus is a mTOR inhibitor that blocks the mTOR pathway, which is involved in cell growth and proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:38:03.225Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Renal cell carcinoma"},{"name":"Soft tissue sarcoma"}]},"trialDetails":[{"nctId":"NCT06653842","phase":"PHASE2","title":"A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Palvella Therapeutics, Inc.","startDate":"2024-12-20","conditions":"Cutaneous Venous Malformations","enrollment":15},{"nctId":"NCT04665739","phase":"PHASE2","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-03","conditions":"Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm","enrollment":70},{"nctId":"NCT05773274","phase":"PHASE2","title":"Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-12","conditions":"Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1","enrollment":100},{"nctId":"NCT02567435","phase":"PHASE3","title":"Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-06-01","conditions":"Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma","enrollment":325},{"nctId":"NCT06239480","phase":"PHASE3","title":"SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Palvella Therapeutics, Inc.","startDate":"2024-07-31","conditions":"Microcystic Lymphatic Malformation","enrollment":51},{"nctId":"NCT00980460","phase":"PHASE3","title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":"PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma","enrollment":236},{"nctId":"NCT05896839","phase":"PHASE1, PHASE2","title":"Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-24","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":16},{"nctId":"NCT01396408","phase":"PHASE2","title":"A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2012-02-09","conditions":"Advanced Rare Tumours","enrollment":137},{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":720},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT03047213","phase":"PHASE2","title":"Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-08-24","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Metastatic Transitional Cell Carcinoma, Metastatic Urothelial Carcinoma","enrollment":17},{"nctId":"NCT01375829","phase":"PHASE1","title":"Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-27","conditions":"Adult Solid Neoplasm","enrollment":22},{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT04141020","phase":"PHASE2","title":"Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms","status":"RECRUITING","sponsor":"University of Miami","startDate":"2021-10-27","conditions":"Cerebral Aneurysm","enrollment":80},{"nctId":"NCT02215720","phase":"PHASE1","title":"Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2011-04-26","conditions":"Patients With Advanced or Metastatic Solid Tumors","enrollment":45},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT05573126","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","status":"RECRUITING","sponsor":"Ellipses Pharma","startDate":"2023-01-11","conditions":"Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer","enrollment":95},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":4200},{"nctId":"NCT03950609","phase":"PHASE2","title":"Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-07-30","conditions":"Advanced Carcinoid Tumor, Digestive System Neuroendocrine Neoplasm, Multiple Endocrine Neoplasia Type 1","enrollment":36},{"nctId":"NCT06708455","phase":"PHASE2","title":"Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Rapa Therapeutics LLC","startDate":"2027-03-01","conditions":"Malignant Melanoma With Metastasis, Malignant Melanoma, Malignant Melanoma Stage IIIc","enrollment":65},{"nctId":"NCT06950385","phase":"PHASE3","title":"Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis","status":"RECRUITING","sponsor":"Rapamycin Holdings Inc.","startDate":"2025-07-18","conditions":"Familial Adenomatous Polyposis (FAP)","enrollment":168},{"nctId":"NCT04485559","phase":"PHASE1","title":"Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2020-12-09","conditions":"Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High Grade Glioma","enrollment":50},{"nctId":"NCT07475546","phase":"PHASE3","title":"Combination Gerotherapeutic Interventions for Healthspan Improvement","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgelessRx","startDate":"2025-07-23","conditions":"Healthspan Improvement, Aging, Longevity","enrollment":30},{"nctId":"NCT07329088","phase":"NA","title":"Isoleucine Addition Treatment Effects in a Controlled Diet Study","status":"NOT_YET_RECRUITING","sponsor":"Jean L. Fry","startDate":"2026-05-04","conditions":"Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Metabolic Syndrome (MetS), Obesity & Overweight","enrollment":40},{"nctId":"NCT03970096","phase":"PHASE2","title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-11-19","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT06752694","phase":"PHASE2","title":"Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-25","conditions":"Aplastic Anemia","enrollment":20},{"nctId":"NCT06437574","phase":"PHASE2","title":"Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2024-07-16","conditions":"Prostate Cancer","enrollment":140},{"nctId":"NCT05810870","phase":"PHASE2","title":"PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2023-05-24","conditions":"Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":14},{"nctId":"NCT02389309","phase":"PHASE1","title":"Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-10-05","conditions":"Advanced Malignant Solid Neoplasm, Recurrent Brain Neoplasm, Recurrent Malignant Solid Neoplasm","enrollment":14},{"nctId":"NCT07443826","phase":"PHASE1, PHASE2","title":"CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy","status":"RECRUITING","sponsor":"Unlimited Biotechnology LLC","startDate":"2026-03-31","conditions":"Age-related Muscle Decline","enrollment":12},{"nctId":"NCT05012371","phase":"PHASE2","title":"Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-16","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8","enrollment":90},{"nctId":"NCT05342519","phase":"PHASE2","title":"Daily Topical Rapamycin for Vitiligo","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2022-07-28","conditions":"Vitiligo","enrollment":20},{"nctId":"NCT07144150","phase":"NA","title":"EVERO Drug-coated Balloon (DCB) Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"Cook Research Incorporated","startDate":"2026-02","conditions":"Peripheral Vascular Disease, Peripheral Arterial Disease","enrollment":410},{"nctId":"NCT04895748","phase":"PHASE1","title":"DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-30","conditions":"Carcinoma, Renal Cell","enrollment":40},{"nctId":"NCT03933904","phase":"PHASE2","title":"Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2019-09-25","conditions":"Castleman Disease, Castleman's Disease, Multicentric","enrollment":7},{"nctId":"NCT06055608","phase":"PHASE2","title":"Advancing Transplantation Outcomes in Children","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-05-22","conditions":"Kidney Transplant","enrollment":200},{"nctId":"NCT02574728","phase":"PHASE2","title":"Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2015-06","conditions":"Cancer","enrollment":46},{"nctId":"NCT06078696","phase":"PHASE1, PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":"Anemia, Sickle Cell","enrollment":1},{"nctId":"NCT07436611","phase":"PHASE2","title":"Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains","status":"NOT_YET_RECRUITING","sponsor":"AFT Pharmaceuticals, Ltd.","startDate":"2026-04","conditions":"Port Wine Stains","enrollment":30},{"nctId":"NCT04469530","phase":"PHASE2","title":"Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-09-16","conditions":"Solid Tumor","enrollment":55},{"nctId":"NCT02184416","phase":"","title":"Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-10-31","conditions":"Metastatic Renal Cell Carcinoma (mRCC)","enrollment":554},{"nctId":"NCT03203525","phase":"PHASE1","title":"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-06-23","conditions":"Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver","enrollment":38},{"nctId":"NCT01946529","phase":"PHASE2","title":"Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-27","conditions":"Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","enrollment":24},{"nctId":"NCT07426484","phase":"PHASE4","title":"Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-07","conditions":"Cutaneous Squamous Cell Carcinoma, Skin Cancer","enrollment":80},{"nctId":"NCT04199026","phase":"NA","title":"Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-25","conditions":"Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma","enrollment":20},{"nctId":"NCT03304678","phase":"PHASE2","title":"Discovery of Sirolimus Sensitive Biomarkers in Blood","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2017-12-04","conditions":"Lymphangioleiomyomatosis","enrollment":33},{"nctId":"NCT07054320","phase":"","title":"Rapamycin and Infection-related Illness","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoskinson Health and Wellness Clinic","startDate":"2025-08-06","conditions":"Infectious Diseases","enrollment":15},{"nctId":"NCT03065062","phase":"PHASE1","title":"Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors","status":"SUSPENDED","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-02-28","conditions":"Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer","enrollment":75},{"nctId":"NCT03504241","phase":"PHASE1","title":"Tolerance by Engaging Antigen During Cellular Homeostasis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-30","conditions":"Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient","enrollment":8},{"nctId":"NCT02397083","phase":"PHASE2","title":"Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-23","conditions":"Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma","enrollment":102},{"nctId":"NCT03972592","phase":"PHASE2","title":"Topical Sirolimus in Cutaneous Lymphatic Malformations","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2019-06-05","conditions":"Vascular Malformations, Lymphatic Malformation","enrollment":55},{"nctId":"NCT03008408","phase":"PHASE2","title":"A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-18","conditions":"Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Carcinoma","enrollment":90},{"nctId":"NCT05949658","phase":"PHASE1","title":"Rapalog Pharmacology (RAP PAC) Study","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2024-05-15","conditions":"Aging","enrollment":72},{"nctId":"NCT03155620","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-07-31","conditions":"Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma","enrollment":1376},{"nctId":"NCT01625351","phase":"PHASE1","title":"A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-08-20","conditions":"Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor","enrollment":23},{"nctId":"NCT02891603","phase":"PHASE1, PHASE2","title":"A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-06-08","conditions":"Graft Vs Host Disease, GVHD","enrollment":40},{"nctId":"NCT06727305","phase":"PHASE1, PHASE2","title":"MTOR Inhibitors in Older Adults","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-02","conditions":"Aging","enrollment":60},{"nctId":"NCT07378657","phase":"PHASE3","title":"Systematic Approach for Children With Orbital Malformation With Sirolimus Use","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-11-01","conditions":"Orbital Lymphatic Malformation","enrollment":30},{"nctId":"NCT07359807","phase":"PHASE2, PHASE3","title":"A Prospective, Randomized, Multi-center Trial Comparing the MagicTouch PTA Sirolimus-coated Balloon to Paclitaxel-coated Balloons for the Treatment of Stenotic or Occluded Femoropopliteal Arteries in Peripheral Arterial Disease (PAD) Patients.","status":"NOT_YET_RECRUITING","sponsor":"Concept Medical Inc.","startDate":"2026-04","conditions":"Popliteal Artery Disease, Superficial Femoral Artery Disease","enrollment":478},{"nctId":"NCT07354620","phase":"EARLY_PHASE1","title":"A Pilot Study on Reverse Aging (The REVERSE Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Christ Hospital","startDate":"2025-02-15","conditions":"Aging","enrollment":52},{"nctId":"NCT05467397","phase":"PHASE1, PHASE2","title":"Feasibility of [11C]Acetate-PET in LAM and TSC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-30","conditions":"Lymphangioleiomyomatosis, Tuberous Sclerosis Complex","enrollment":7},{"nctId":"NCT07352852","phase":"","title":"Rapamycin-Eluting Vertebral Stents In The Real-World Treatment of Symptomatic Intracranial Atherosclerotic Stenosis","status":"RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2025-05-14","conditions":"Intracranial Arterial Stenosis, Brain Diseases","enrollment":300},{"nctId":"NCT01087554","phase":"PHASE1","title":"Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-03","conditions":"Advanced Cancer","enrollment":249},{"nctId":"NCT02979873","phase":"PHASE2","title":"Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2016-12-19","conditions":"Severe Aplastic Anemia","enrollment":84},{"nctId":"NCT04789070","phase":"PHASE3","title":"Phase III Trial of Sirolimus in IBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2022-07-01","conditions":"Inclusion Body Myositis","enrollment":140},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT03065387","phase":"PHASE1","title":"Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-31","conditions":"Advanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation","enrollment":93},{"nctId":"NCT06528301","phase":"PHASE1","title":"A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies","status":"RECRUITING","sponsor":"Umoja Biopharma","startDate":"2025-03-10","conditions":"Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL)","enrollment":106},{"nctId":"NCT06310291","phase":"EARLY_PHASE1","title":"VTP-1000 in Adults With Celiac Disease","status":"RECRUITING","sponsor":"Barinthus Biotherapeutics","startDate":"2024-08-01","conditions":"Celiac Disease","enrollment":45},{"nctId":"NCT07002177","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC","status":"RECRUITING","sponsor":"Forward Pharmaceuticals Co., Ltd.","startDate":"2025-06-01","conditions":"Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II","enrollment":196},{"nctId":"NCT00975819","phase":"PHASE2","title":"Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies","status":"COMPLETED","sponsor":"Denise Martin Adams","startDate":"2009-10","conditions":"Kaposiform Hemangioendotheliomas, Tufted Angioma, Capillary Venous Lymphatic Malformation","enrollment":61},{"nctId":"NCT05384756","phase":"PHASE1","title":"TMLI and Alemtuzumab for Treatment of Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-07-13","conditions":"Sickle Cell Disease","enrollment":2},{"nctId":"NCT04542733","phase":"NA","title":"The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus and Leflunomide in Treatment of BK Virus Infection in Kidney Transplantation Recipient","status":"RECRUITING","sponsor":"King Chulalongkorn Memorial Hospital","startDate":"2021-02-10","conditions":"Kidney Transplant Infection, BK Virus Infection","enrollment":50},{"nctId":"NCT04172922","phase":"PHASE1","title":"Topical Rapamycin/Sirolimus for Complicated Vascular Anomalies and Other Susceptible Lesions","status":"TERMINATED","sponsor":"Nemours Children's Clinic","startDate":"2020-04-01","conditions":"Vascular Anomaly","enrollment":5},{"nctId":"NCT05836025","phase":"PHASE2","title":"Effect of Rapamycin in Ovarian Aging","status":"ACTIVE_NOT_RECRUITING","sponsor":"Columbia University","startDate":"2023-06-01","conditions":"Perimenopausal","enrollment":50},{"nctId":"NCT00133887","phase":"PHASE3","title":"TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2004-04","conditions":"Skin Cancer, Kidney Transplantation","enrollment":77},{"nctId":"NCT07302932","phase":"NA","title":"Metformin and Molecular Aging in Prediabetes","status":"COMPLETED","sponsor":"Diabetes Foundation, India","startDate":"2023-02-01","conditions":"Metformin, Prediabetes","enrollment":112},{"nctId":"NCT05105152","phase":"PHASE1","title":"PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2021-11-29","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse","enrollment":18},{"nctId":"NCT02509468","phase":"PHASE2","title":"suPERficial Slow-flow Vascular malFORMations Treated With sirolimUS","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2015-09-30","conditions":"Vascular Malformation","enrollment":63},{"nctId":"NCT01282697","phase":"PHASE1","title":"Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2011-04-22","conditions":"Refractory Solid Tumors in Children","enrollment":42},{"nctId":"NCT07062965","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-05","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT04083183","phase":"PHASE1, PHASE2","title":"Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-06-16","conditions":"Non-Malignant Neoplasm","enrollment":40},{"nctId":"NCT05009992","phase":"PHASE2","title":"Combination Therapy for the Treatment of Diffuse Midline Gliomas","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2021-10-20","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma","enrollment":360},{"nctId":"NCT03243019","phase":"PHASE2","title":"Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2018-06-25","conditions":"Lymphatic Malformation, Pediatric","enrollment":28},{"nctId":"NCT04948203","phase":"PHASE2, PHASE3","title":"Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2021-07-09","conditions":"Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID","enrollment":60},{"nctId":"NCT04177004","phase":"PHASE1","title":"Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-04-30","conditions":"Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":53},{"nctId":"NCT05835999","phase":"PHASE2","title":"Everolimus Aging Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-03-24","conditions":"Aging, Insulin Resistance","enrollment":106},{"nctId":"NCT03952637","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis","status":"RECRUITING","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2019-08-19","conditions":"Lysosomal Diseases, Gangliosidosis, GM1","enrollment":54},{"nctId":"NCT01869114","phase":"PHASE2","title":"Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2013-07-08","conditions":"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","enrollment":57},{"nctId":"NCT03363763","phase":"PHASE2","title":"Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex","status":"TERMINATED","sponsor":"Aucta Pharmaceuticals, Inc","startDate":"2017-04-12","conditions":"Angiofibroma of Face, Tuberous Sclerosis","enrollment":24},{"nctId":"NCT06881927","phase":"PHASE4","title":"Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-02-01","conditions":"Sepsis and Septic Shock, Acute Respiratory Failure, Kidney Transplant Recipients","enrollment":212},{"nctId":"NCT01885689","phase":"PHASE2","title":"Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2014-02-10","conditions":"Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission","enrollment":72},{"nctId":"NCT05661461","phase":"PHASE1","title":"Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment","status":"RECRUITING","sponsor":"Aadi Bioscience, Inc.","startDate":"2022-11-23","conditions":"Tumor, Solid, Tumor, Advanced Solid Tumor","enrollment":28},{"nctId":"NCT00600496","phase":"PHASE1","title":"A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2007-12-14","conditions":"Breast Cancer, Breast Neoplasms, Colon Cancer","enrollment":140},{"nctId":"NCT02321501","phase":"PHASE1","title":"Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-06-22","conditions":"ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":37},{"nctId":"NCT00776373","phase":"PHASE1, PHASE2","title":"Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies","status":"TERMINATED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2007-01","conditions":"ALL, Burkitt's Lymphoma, Lymphoblastic Leukemia","enrollment":4},{"nctId":"NCT00977574","phase":"PHASE2","title":"Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":"Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma","enrollment":349},{"nctId":"NCT01187199","phase":"PHASE1","title":"Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-08-19","conditions":"Advanced Cancer","enrollment":278},{"nctId":"NCT03334617","phase":"PHASE2","title":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-12-18","conditions":"Non-Small Cell Lung Cancer","enrollment":528},{"nctId":"NCT01582191","phase":"PHASE1","title":"Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-05-14","conditions":"Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm","enrollment":151}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Torisel"],"phase":"phase_3","status":"active","brandName":"Temsirolimus (CCI-779)","genericName":"Temsirolimus (CCI-779)","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Temsirolimus, also known as CCI-779, is a small molecule inhibitor of the FKBP1A protein. It is used in clinical trials for various conditions, including triple-negative breast cancer, sepsis, and kidney transplant recipients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}